Kumar Visvanathan
About
In The Last Decade
Kumar Visvanathan
121 papers receiving 3.7k citations
Peers
Comparison fields: 5 of 114
- Epidemiology 2.4k
- Hepatology 1.8k
- Immunology 960
- Infectious Diseases 468
- Molecular Biology 415
Countries citing papers authored by Kumar Visvanathan
This map shows the geographic impact of Kumar Visvanathan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kumar Visvanathan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kumar Visvanathan more than expected).
Fields of papers citing papers by Kumar Visvanathan
This network shows the impact of papers produced by Kumar Visvanathan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kumar Visvanathan. The network helps show where Kumar Visvanathan may publish in the future.
Co-authorship network of co-authors of Kumar Visvanathan
This figure shows the co-authorship network connecting the top 25 collaborators of Kumar Visvanathan. A scholar is included among the top collaborators of Kumar Visvanathan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kumar Visvanathan. Kumar Visvanathan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 40 | |
| 3 | 30 | |
| 4 | 9 | |
| 5 | 13 | |
| 6 | Safety, Pharmacokinetics and Pharmacodynamics of Oral TLR8 Agonist GS-9688 in Patients with Chronic Hepatitis B: A Randomized, Placebo-Controlled, Double-Blind Phase 1b Study | 2 |
| 7 | 9 | |
| 8 | 15 | |
| 9 | 10 | |
| 10 | 4 | |
| 11 | 84 | |
| 12 | Clinical and virological factors that predict post partum flares in pregnant women with chronic HBV | 1 |
| 13 | Safety and Pharmacodynamics of Oral TLR-7 agonist GS-9620 in patients with Chronic Hepatitis B | 4 |
| 14 | 22 | |
| 15 | 354 | |
| 16 | 56 | |
| 17 | 36 | |
| 18 | 41 | |
| 19 | Up-regulation of toll-like receptor expression in chronic hepatitis C: Correlation with circulating pro-inflammatory cytokine levels and hepatic necro-inflammatory activity | 2 |
| 20 | 8 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.